Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer

Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer

Abstract Background Breast cancer is a complex disease with a highly immunosuppressive tumor microenvironment, and has limited clinical response to immune checkpoint blockade (ICB) therapy. T-helper 2 (Th2) cells, an important component of the tumor microenvironment (TME), play an essential role in...

Full description

Bibliographic Details
Main Authors: Yuru Chen, Jiazheng Sun, Yachan Luo, Jiazhou Liu, Xiaoyu Wang, Rui Feng, Jing Huang, Huimin Du, Qin Li, Jinxiang Tan, Guosheng Ren, Xiaoyi Wang, Hongzhong Li
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Journal of Translational Medicine
Subjects:
Th2 cell
Suplatast tosilate
Breast cancer
Immune checkpoint blockade
Immunotherapy
Online Access:https://doi.org/10.1186/s12967-022-03807-8

Internet

https://doi.org/10.1186/s12967-022-03807-8

Similar Items